Skip to content
Sign in

ORMP · NASDAQ

Oramed Pharmaceuticals (ORMP) Stock Price & Fundamentals

$361.75+0.45%+$1.63End-of-day price as of Oct 9, 2026

Oramed Pharmaceuticals (ORMP) closed at $361.75 on Oct 9, 2026, up 0.45% from the previous close of $360.12.

Share price, past year

1Y +1.57%

52-week range $336.27 – $416.64. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$361.75
Sep 30, 2026$360.29
Aug 31, 2026$350.94
Jul 31, 2026$343.75
Jun 30, 2026$356.03
May 29, 2026$404.83
Apr 30, 2026$387.94
Mar 31, 2026$404.52
Feb 27, 2026$387.42
Jan 30, 2026$371.87
Dec 31, 2025$359.95
Nov 28, 2025$348.68
Oct 31, 2025$349.43

Key statistics

Market cap
$14.95B
P/E (TTM)
87.6
EPS (TTM)
$4.13
Revenue (TTM)
—
Net income (TTM)
$174.87M
Shares outstanding
41.3M
Dividend yield
—
52-week range
$336.27 – $416.64

Oramed Pharmaceuticals's market cap is $14.95B, based on a share price of $361.75 and 41.3M shares outstanding as of Jun 30, 2026.

Financials

Oramed Pharmaceuticals reported revenue of $2.00M for fiscal 2025.

Oramed Pharmaceuticals earned net income of $64.05M in fiscal 2025, a net margin of 3,202.5%.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY25
Annual revenue by fiscal year; the table below lists the values.
Oramed Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$2.00M+49.3%$64.05M3,202.5%$1.50−$9.15M
FY2023ended Dec 31, 2023$1.34M−50.4%$5.09M379.7%$0.14−$10.55M
FY2022ended Dec 31, 2022$2.70M0.0%−$36.56M−1,352.6%−$0.94−$28.41M
FY2021ended Aug 31, 2021$2.70M−0.3%−$22.99M−850.5%$0.78−$21.56M
FY2020ended Aug 31, 2020$2.71M+0.3%−$11.51M−424.8%$0.56−$12.52M
FY2019ended Aug 31, 2019$2.70M+10.4%−$14.36M−531.1%$0.82−$12.96M
FY2018ended Aug 31, 2018$2.45M−0.3%−$12.73M−519.7%$0.86−$14.66M
FY2017ended Aug 31, 2017$2.46M+283.2%−$10.48M−426.7%$0.79−$5.84M
FY2016ended Aug 31, 2016$641.00K—−$10.96M−1,710.5%$0.87$4.65M
Oramed Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q1 FY2025ended Mar 31, 2025$2.00M−$7.64M−$0.19
Q2 FY2023ended Jun 30, 2023$674.00K——
Q1 FY2023ended Mar 31, 2023$666.00K——
Q4 FY2022ended Dec 31, 2022$681.00K——
Q3 FY2022ended Sep 30, 2022$682.00K——
Q2 FY2022ended Jun 30, 2022$674.00K——
Q1 FY2022ended Mar 31, 2022$666.00K——
Q4 FY2021ended Aug 31, 2021$689.00K——

Company profile

Name
Oramed Pharmaceuticals Inc.
Ticker
ORMP
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
1185 Avenue Of The Americas, 3rd Floor, New York, NY 10036
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001176309

Recent SEC filings

Frequently asked questions

What is Oramed Pharmaceuticals's stock price?

Oramed Pharmaceuticals (ORMP) closed at $361.75 on Oct 9, 2026, up 0.45% from the previous close of $360.12.

What is Oramed Pharmaceuticals's market cap?

Oramed Pharmaceuticals's market cap is $14.95B, based on a share price of $361.75 and 41.3M shares outstanding as of Jun 30, 2026.

How much revenue does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals reported revenue of $2.00M for fiscal 2025.

What is ORMP's P/E ratio?

Oramed Pharmaceuticals's price-to-earnings ratio is 87.6, based on trailing twelve-month diluted EPS of $4.13.

Does Oramed Pharmaceuticals pay a dividend?

Oramed Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Oramed Pharmaceuticals Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures